Our Company

Helix Therapeutics is a seed stage company based on technology discovered in the laboratory of Peter Glazer MD/PhD and licensed on a world wide, exclusive basis from Yale University. Targeted DNA modifications can be designed to:

• » correct mutations, leading to restoration of normal function of key gene products
• » alter levels of gene expression, potentially turning genes on or off
• » functionally disrupt molecules, such as the CCR5 receptor, which mediates HIV entry into T cells

The ability to target specific DNA sequences and modify those sequences without the use of viral vectors is a tremendous advance in the art of gene alteration. When applied to stem cells of the blood, this gene correction technology has the potential to provide stable, heritable corrections of mutations that cause serious diseases such as sickle cell disease, beta-thalassemia and Gaucher’s disease.